Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Radioimmunotherapy Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Beta-emitting
1.2.3 Targeted Alpha Therapy
1.3 Market by Application
1.3.1 Global Radioimmunotherapy Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Solid Tumor
1.3.3 Non Hodgkin Lymphoma
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Radioimmunotherapy Market Perspective (2018-2029)
2.2 Global Radioimmunotherapy Growth Trends by Region
2.2.1 Radioimmunotherapy Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Radioimmunotherapy Historic Market Size by Region (2018-2024)
2.2.3 Radioimmunotherapy Forecasted Market Size by Region (2024-2029)
2.3 Radioimmunotherapy Market Dynamics
2.3.1 Radioimmunotherapy Industry Trends
2.3.2 Radioimmunotherapy Market Drivers
2.3.3 Radioimmunotherapy Market Challenges
2.3.4 Radioimmunotherapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Radioimmunotherapy by Players
3.1.1 Global Radioimmunotherapy Revenue by Players (2018-2024)
3.1.2 Global Radioimmunotherapy Revenue Market Share by Players (2018-2024)
3.2 Global Radioimmunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Radioimmunotherapy, Ranking by Revenue, 2021 VS 2022 VS 2024
3.4 Global Radioimmunotherapy Market Concentration Ratio
3.4.1 Global Radioimmunotherapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Radioimmunotherapy Revenue in 2022
3.5 Global Key Players of Radioimmunotherapy Head office and Area Served
3.6 Global Key Players of Radioimmunotherapy, Product and Application
3.7 Global Key Players of Radioimmunotherapy, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Radioimmunotherapy Breakdown Data by Type
4.1 Global Radioimmunotherapy Historic Market Size by Type (2018-2024)
4.2 Global Radioimmunotherapy Forecasted Market Size by Type (2024-2029)
5 Radioimmunotherapy Breakdown Data by Application
5.1 Global Radioimmunotherapy Historic Market Size by Application (2018-2024)
5.2 Global Radioimmunotherapy Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Radioimmunotherapy Market Size (2018-2029)
6.2 North America Radioimmunotherapy Market Size by Type
6.2.1 North America Radioimmunotherapy Market Size by Type (2018-2024)
6.2.2 North America Radioimmunotherapy Market Size by Type (2024-2029)
6.2.3 North America Radioimmunotherapy Market Share by Type (2018-2029)
6.3 North America Radioimmunotherapy Market Size by Application
6.3.1 North America Radioimmunotherapy Market Size by Application (2018-2024)
6.3.2 North America Radioimmunotherapy Market Size by Application (2024-2029)
6.3.3 North America Radioimmunotherapy Market Share by Application (2018-2029)
6.4 North America Radioimmunotherapy Market Size by Country
6.4.1 North America Radioimmunotherapy Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Radioimmunotherapy Market Size by Country (2018-2024)
6.4.3 North America Radioimmunotherapy Market Size by Country (2024-2029)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Radioimmunotherapy Market Size (2018-2029)
7.2 Europe Radioimmunotherapy Market Size by Type
7.2.1 Europe Radioimmunotherapy Market Size by Type (2018-2024)
7.2.2 Europe Radioimmunotherapy Market Size by Type (2024-2029)
7.2.3 Europe Radioimmunotherapy Market Share by Type (2018-2029)
7.3 Europe Radioimmunotherapy Market Size by Application
7.3.1 Europe Radioimmunotherapy Market Size by Application (2018-2024)
7.3.2 Europe Radioimmunotherapy Market Size by Application (2024-2029)
7.3.3 Europe Radioimmunotherapy Market Share by Application (2018-2029)
7.4 Europe Radioimmunotherapy Market Size by Country
7.4.1 Europe Radioimmunotherapy Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Radioimmunotherapy Market Size by Country (2018-2024)
7.4.3 Europe Radioimmunotherapy Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Radioimmunotherapy Market Size (2018-2029)
8.2 China Radioimmunotherapy Market Size by Type
8.2.1 China Radioimmunotherapy Market Size by Type (2018-2024)
8.2.2 China Radioimmunotherapy Market Size by Type (2024-2029)
8.2.3 China Radioimmunotherapy Market Share by Type (2018-2029)
8.3 China Radioimmunotherapy Market Size by Application
8.3.1 China Radioimmunotherapy Market Size by Application (2018-2024)
8.3.2 China Radioimmunotherapy Market Size by Application (2024-2029)
8.3.3 China Radioimmunotherapy Market Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Radioimmunotherapy Market Size (2018-2029)
9.2 Asia Radioimmunotherapy Market Size by Type
9.2.1 Asia Radioimmunotherapy Market Size by Type (2018-2024)
9.2.2 Asia Radioimmunotherapy Market Size by Type (2024-2029)
9.2.3 Asia Radioimmunotherapy Market Share by Type (2018-2029)
9.3 Asia Radioimmunotherapy Market Size by Application
9.3.1 Asia Radioimmunotherapy Market Size by Application (2018-2024)
9.3.2 Asia Radioimmunotherapy Market Size by Application (2024-2029)
9.3.3 Asia Radioimmunotherapy Market Share by Application (2018-2029)
9.4 Asia Radioimmunotherapy Market Size by Region
9.4.1 Asia Radioimmunotherapy Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Radioimmunotherapy Market Size by Region (2018-2024)
9.4.3 Asia Radioimmunotherapy Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Radioimmunotherapy Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Radioimmunotherapy Market Size by Type
10.2.1 Middle East, Africa, and Latin America Radioimmunotherapy Market Size by Type (2018-2024)
10.2.2 Middle East, Africa, and Latin America Radioimmunotherapy Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Radioimmunotherapy Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Radioimmunotherapy Market Size by Application
10.3.1 Middle East, Africa, and Latin America Radioimmunotherapy Market Size by Application (2018-2024)
10.3.2 Middle East, Africa, and Latin America Radioimmunotherapy Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Radioimmunotherapy Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Radioimmunotherapy Market Size by Country
10.4.1 Middle East, Africa, and Latin America Radioimmunotherapy Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Radioimmunotherapy Market Size by Country (2018-2024)
10.4.3 Middle East, Africa, and Latin America Radioimmunotherapy Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Bayer
11.1.1 Bayer Company Details
11.1.2 Bayer Business Overview
11.1.3 Bayer Radioimmunotherapy Introduction
11.1.4 Bayer Revenue in Radioimmunotherapy Business (2018-2024)
11.1.5 Bayer Recent Developments
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Radioimmunotherapy Introduction
11.2.4 Novartis Revenue in Radioimmunotherapy Business (2018-2024)
11.2.5 Novartis Recent Developments
11.3 Lantheus
11.3.1 Lantheus Company Details
11.3.2 Lantheus Business Overview
11.3.3 Lantheus Radioimmunotherapy Introduction
11.3.4 Lantheus Revenue in Radioimmunotherapy Business (2018-2024)
11.3.5 Lantheus Recent Developments
11.4 Aurobindo Pharma
11.4.1 Aurobindo Pharma Company Details
11.4.2 Aurobindo Pharma Business Overview
11.4.3 Aurobindo Pharma Radioimmunotherapy Introduction
11.4.4 Aurobindo Pharma Revenue in Radioimmunotherapy Business (2018-2024)
11.4.5 Aurobindo Pharma Recent Developments
11.5 Mundipharma
11.5.1 Mundipharma Company Details
11.5.2 Mundipharma Business Overview
11.5.3 Mundipharma Radioimmunotherapy Introduction
11.5.4 Mundipharma Revenue in Radioimmunotherapy Business (2018-2024)
11.5.5 Mundipharma Recent Developments
11.6 China Isotope & Radiation
11.6.1 China Isotope & Radiation Company Details
11.6.2 China Isotope & Radiation Business Overview
11.6.3 China Isotope & Radiation Radioimmunotherapy Introduction
11.6.4 China Isotope & Radiation Revenue in Radioimmunotherapy Business (2018-2024)
11.6.5 China Isotope & Radiation Recent Developments
11.7 Curium Pharmaceuticals
11.7.1 Curium Pharmaceuticals Company Details
11.7.2 Curium Pharmaceuticals Business Overview
11.7.3 Curium Pharmaceuticals Radioimmunotherapy Introduction
11.7.4 Curium Pharmaceuticals Revenue in Radioimmunotherapy Business (2018-2024)
11.7.5 Curium Pharmaceuticals Recent Developments
11.8 Gilead Sciences
11.8.1 Gilead Sciences Company Details
11.8.2 Gilead Sciences Business Overview
11.8.3 Gilead Sciences Radioimmunotherapy Introduction
11.8.4 Gilead Sciences Revenue in Radioimmunotherapy Business (2018-2024)
11.8.5 Gilead Sciences Recent Developments
11.9 Clarity Pharmaceuticals
11.9.1 Clarity Pharmaceuticals Company Details
11.9.2 Clarity Pharmaceuticals Business Overview
11.9.3 Clarity Pharmaceuticals Radioimmunotherapy Introduction
11.9.4 Clarity Pharmaceuticals Revenue in Radioimmunotherapy Business (2018-2024)
11.9.5 Clarity Pharmaceuticals Recent Developments
11.10 Curasight
11.10.1 Curasight Company Details
11.10.2 Curasight Business Overview
11.10.3 Curasight Radioimmunotherapy Introduction
11.10.4 Curasight Revenue in Radioimmunotherapy Business (2018-2024)
11.10.5 Curasight Recent Developments
11.11 Nordic Nanovector
11.11.1 Nordic Nanovector Company Details
11.11.2 Nordic Nanovector Business Overview
11.11.3 Nordic Nanovector Radioimmunotherapy Introduction
11.11.4 Nordic Nanovector Revenue in Radioimmunotherapy Business (2018-2024)
11.11.5 Nordic Nanovector Recent Developments
11.12 Philogen
11.12.1 Philogen Company Details
11.12.2 Philogen Business Overview
11.12.3 Philogen Radioimmunotherapy Introduction
11.12.4 Philogen Revenue in Radioimmunotherapy Business (2018-2024)
11.12.5 Philogen Recent Developments
11.13 RadioMedix
11.13.1 RadioMedix Company Details
11.13.2 RadioMedix Business Overview
11.13.3 RadioMedix Radioimmunotherapy Introduction
11.13.4 RadioMedix Revenue in Radioimmunotherapy Business (2018-2024)
11.13.5 RadioMedix Recent Developments
11.14 Telix Pharmaceuticals
11.14.1 Telix Pharmaceuticals Company Details
11.14.2 Telix Pharmaceuticals Business Overview
11.14.3 Telix Pharmaceuticals Radioimmunotherapy Introduction
11.14.4 Telix Pharmaceuticals Revenue in Radioimmunotherapy Business (2018-2024)
11.14.5 Telix Pharmaceuticals Recent Developments
11.15 Orano Med
11.15.1 Orano Med Company Details
11.15.2 Orano Med Business Overview
11.15.3 Orano Med Radioimmunotherapy Introduction
11.15.4 Orano Med Revenue in Radioimmunotherapy Business (2018-2024)
11.15.5 Orano Med Recent Developments
11.16 Actinium Pharmaceuticals
11.16.1 Actinium Pharmaceuticals Company Details
11.16.2 Actinium Pharmaceuticals Business Overview
11.16.3 Actinium Pharmaceuticals Radioimmunotherapy Introduction
11.16.4 Actinium Pharmaceuticals Revenue in Radioimmunotherapy Business (2018-2024)
11.16.5 Actinium Pharmaceuticals Recent Developments
11.17 Y-mAbs Therapeutics
11.17.1 Y-mAbs Therapeutics Company Details
11.17.2 Y-mAbs Therapeutics Business Overview
11.17.3 Y-mAbs Therapeutics Radioimmunotherapy Introduction
11.17.4 Y-mAbs Therapeutics Revenue in Radioimmunotherapy Business (2018-2024)
11.17.5 Y-mAbs Therapeutics Recent Developments
11.18 Fusion Pharmaceuticals
11.18.1 Fusion Pharmaceuticals Company Details
11.18.2 Fusion Pharmaceuticals Business Overview
11.18.3 Fusion Pharmaceuticals Radioimmunotherapy Introduction
11.18.4 Fusion Pharmaceuticals Revenue in Radioimmunotherapy Business (2018-2024)
11.18.5 Fusion Pharmaceuticals Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Radioimmunotherapy Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of Beta-emitting
Table 3. Key Players of Targeted Alpha Therapy
Table 4. Global Radioimmunotherapy Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
Table 5. Global Radioimmunotherapy Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Radioimmunotherapy Market Size by Region (2018-2024) & (US$ Million)
Table 7. Global Radioimmunotherapy Market Share by Region (2018-2024)
Table 8. Global Radioimmunotherapy Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 9. Global Radioimmunotherapy Market Share by Region (2024-2029)
Table 10. Radioimmunotherapy Market Trends
Table 11. Radioimmunotherapy Market Drivers
Table 12. Radioimmunotherapy Market Challenges
Table 13. Radioimmunotherapy Market Restraints
Table 14. Global Radioimmunotherapy Revenue by Players (2018-2024) & (US$ Million)
Table 15. Global Radioimmunotherapy Revenue Share by Players (2018-2024)
Table 16. Global Top Radioimmunotherapy by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radioimmunotherapy as of 2022)
Table 17. Global Radioimmunotherapy Industry Ranking 2021 VS 2022 VS 2024
Table 18. Global 5 Largest Players Market Share by Radioimmunotherapy Revenue (CR5 and HHI) & (2018-2024)
Table 19. Global Key Players of Radioimmunotherapy, Headquarters and Area Served
Table 20. Global Key Players of Radioimmunotherapy, Product and Application
Table 21. Global Key Players of Radioimmunotherapy, Product and Application
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Radioimmunotherapy Market Size by Type (2018-2024) & (US$ Million)
Table 24. Global Radioimmunotherapy Revenue Market Share by Type (2018-2024)
Table 25. Global Radioimmunotherapy Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 26. Global Radioimmunotherapy Revenue Market Share by Type (2024-2029)
Table 27. Global Radioimmunotherapy Market Size by Application (2018-2024) & (US$ Million)
Table 28. Global Radioimmunotherapy Revenue Share by Application (2018-2024)
Table 29. Global Radioimmunotherapy Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 30. Global Radioimmunotherapy Revenue Share by Application (2024-2029)
Table 31. North America Radioimmunotherapy Market Size by Type (2018-2024) & (US$ Million)
Table 32. North America Radioimmunotherapy Market Size by Type (2024-2029) & (US$ Million)
Table 33. North America Radioimmunotherapy Market Size by Application (2018-2024) & (US$ Million)
Table 34. North America Radioimmunotherapy Market Size by Application (2024-2029) & (US$ Million)
Table 35. North America Radioimmunotherapy Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 36. North America Radioimmunotherapy Market Size by Country (2018-2024) & (US$ Million)
Table 37. North America Radioimmunotherapy Market Size by Country (2024-2029) & (US$ Million)
Table 38. Europe Radioimmunotherapy Market Size by Type (2018-2024) & (US$ Million)
Table 39. Europe Radioimmunotherapy Market Size by Type (2024-2029) & (US$ Million)
Table 40. Europe Radioimmunotherapy Market Size by Application (2018-2024) & (US$ Million)
Table 41. Europe Radioimmunotherapy Market Size by Application (2024-2029) & (US$ Million)
Table 42. Europe Radioimmunotherapy Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 43. Europe Radioimmunotherapy Market Size by Country (2018-2024) & (US$ Million)
Table 44. Europe Radioimmunotherapy Market Size by Country (2024-2029) & (US$ Million)
Table 45. China Radioimmunotherapy Market Size by Type (2018-2024) & (US$ Million)
Table 46. China Radioimmunotherapy Market Size by Type (2024-2029) & (US$ Million)
Table 47. China Radioimmunotherapy Market Size by Application (2018-2024) & (US$ Million)
Table 48. China Radioimmunotherapy Market Size by Application (2024-2029) & (US$ Million)
Table 49. Asia Radioimmunotherapy Market Size by Type (2018-2024) & (US$ Million)
Table 50. Asia Radioimmunotherapy Market Size by Type (2024-2029) & (US$ Million)
Table 51. Asia Radioimmunotherapy Market Size by Application (2018-2024) & (US$ Million)
Table 52. Asia Radioimmunotherapy Market Size by Application (2024-2029) & (US$ Million)
Table 53. Asia Radioimmunotherapy Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 54. Asia Radioimmunotherapy Market Size by Region (2018-2024) & (US$ Million)
Table 55. Asia Radioimmunotherapy Market Size by Region (2024-2029) & (US$ Million)
Table 56. Middle East, Africa, and Latin America Radioimmunotherapy Market Size by Type (2018-2024) & (US$ Million)
Table 57. Middle East, Africa, and Latin America Radioimmunotherapy Market Size by Type (2024-2029) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Radioimmunotherapy Market Size by Application (2018-2024) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Radioimmunotherapy Market Size by Application (2024-2029) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Radioimmunotherapy Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 61. Middle East, Africa, and Latin America Radioimmunotherapy Market Size by Country (2018-2024) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Radioimmunotherapy Market Size by Country (2024-2029) & (US$ Million)
Table 63. Bayer Company Details
Table 64. Bayer Business Overview
Table 65. Bayer Radioimmunotherapy Product
Table 66. Bayer Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million)
Table 67. Bayer Recent Developments
Table 68. Novartis Company Details
Table 69. Novartis Business Overview
Table 70. Novartis Radioimmunotherapy Product
Table 71. Novartis Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million)
Table 72. Novartis Recent Developments
Table 73. Lantheus Company Details
Table 74. Lantheus Business Overview
Table 75. Lantheus Radioimmunotherapy Product
Table 76. Lantheus Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million)
Table 77. Lantheus Recent Developments
Table 78. Aurobindo Pharma Company Details
Table 79. Aurobindo Pharma Business Overview
Table 80. Aurobindo Pharma Radioimmunotherapy Product
Table 81. Aurobindo Pharma Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million)
Table 82. Aurobindo Pharma Recent Developments
Table 83. Mundipharma Company Details
Table 84. Mundipharma Business Overview
Table 85. Mundipharma Radioimmunotherapy Product
Table 86. Mundipharma Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million)
Table 87. Mundipharma Recent Developments
Table 88. China Isotope & Radiation Company Details
Table 89. China Isotope & Radiation Business Overview
Table 90. China Isotope & Radiation Radioimmunotherapy Product
Table 91. China Isotope & Radiation Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million)
Table 92. China Isotope & Radiation Recent Developments
Table 93. Curium Pharmaceuticals Company Details
Table 94. Curium Pharmaceuticals Business Overview
Table 95. Curium Pharmaceuticals Radioimmunotherapy Product
Table 96. Curium Pharmaceuticals Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million)
Table 97. Curium Pharmaceuticals Recent Developments
Table 98. Gilead Sciences Company Details
Table 99. Gilead Sciences Business Overview
Table 100. Gilead Sciences Radioimmunotherapy Product
Table 101. Gilead Sciences Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million)
Table 102. Gilead Sciences Recent Developments
Table 103. Clarity Pharmaceuticals Company Details
Table 104. Clarity Pharmaceuticals Business Overview
Table 105. Clarity Pharmaceuticals Radioimmunotherapy Product
Table 106. Clarity Pharmaceuticals Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million)
Table 107. Clarity Pharmaceuticals Recent Developments
Table 108. Curasight Company Details
Table 109. Curasight Business Overview
Table 110. Curasight Radioimmunotherapy Product
Table 111. Curasight Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million)
Table 112. Curasight Recent Developments
Table 113. Nordic Nanovector Company Details
Table 114. Nordic Nanovector Business Overview
Table 115. Nordic Nanovector Radioimmunotherapy Product
Table 116. Nordic Nanovector Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million)
Table 117. Nordic Nanovector Recent Developments
Table 118. Philogen Company Details
Table 119. Philogen Business Overview
Table 120. Philogen Radioimmunotherapy Product
Table 121. Philogen Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million)
Table 122. Philogen Recent Developments
Table 123. RadioMedix Company Details
Table 124. RadioMedix Business Overview
Table 125. RadioMedix Radioimmunotherapy Product
Table 126. RadioMedix Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million)
Table 127. RadioMedix Recent Developments
Table 128. Telix Pharmaceuticals Company Details
Table 129. Telix Pharmaceuticals Business Overview
Table 130. Telix Pharmaceuticals Radioimmunotherapy Product
Table 131. Telix Pharmaceuticals Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million)
Table 132. Telix Pharmaceuticals Recent Developments
Table 133. Orano Med Company Details
Table 134. Orano Med Business Overview
Table 135. Orano Med Radioimmunotherapy Product
Table 136. Orano Med Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million)
Table 137. Orano Med Recent Developments
Table 138. Actinium Pharmaceuticals Company Details
Table 139. Actinium Pharmaceuticals Business Overview
Table 140. Actinium Pharmaceuticals Radioimmunotherapy Product
Table 141. Actinium Pharmaceuticals Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million)
Table 142. Actinium Pharmaceuticals Recent Developments
Table 143. Y-mAbs Therapeutics Company Details
Table 144. Y-mAbs Therapeutics Business Overview
Table 145. Y-mAbs Therapeutics Radioimmunotherapy Product
Table 146. Y-mAbs Therapeutics Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million)
Table 147. Y-mAbs Therapeutics Recent Developments
Table 148. Fusion Pharmaceuticals Company Details
Table 149. Fusion Pharmaceuticals Business Overview
Table 150. Fusion Pharmaceuticals Radioimmunotherapy Product
Table 151. Fusion Pharmaceuticals Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million)
Table 152. Fusion Pharmaceuticals Recent Developments
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Radioimmunotherapy Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global Radioimmunotherapy Market Share by Type: 2022 VS 2029
Figure 3. Beta-emitting Features
Figure 4. Targeted Alpha Therapy Features
Figure 5. Global Radioimmunotherapy Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 6. Global Radioimmunotherapy Market Share by Application: 2022 VS 2029
Figure 7. Solid Tumor Case Studies
Figure 8. Non Hodgkin Lymphoma Case Studies
Figure 9. Radioimmunotherapy Report Years Considered
Figure 10. Global Radioimmunotherapy Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 11. Global Radioimmunotherapy Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 12. Global Radioimmunotherapy Market Share by Region: 2022 VS 2029
Figure 13. Global Radioimmunotherapy Market Share by Players in 2022
Figure 14. Global Top Radioimmunotherapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radioimmunotherapy as of 2022)
Figure 15. The Top 10 and 5 Players Market Share by Radioimmunotherapy Revenue in 2022
Figure 16. North America Radioimmunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 17. North America Radioimmunotherapy Market Share by Type (2018-2029)
Figure 18. North America Radioimmunotherapy Market Share by Application (2018-2029)
Figure 19. North America Radioimmunotherapy Market Share by Country (2018-2029)
Figure 20. United States Radioimmunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. Canada Radioimmunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. Europe Radioimmunotherapy Market Size YoY (2018-2029) & (US$ Million)
Figure 23. Europe Radioimmunotherapy Market Share by Type (2018-2029)
Figure 24. Europe Radioimmunotherapy Market Share by Application (2018-2029)
Figure 25. Europe Radioimmunotherapy Market Share by Country (2018-2029)
Figure 26. Germany Radioimmunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. France Radioimmunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. U.K. Radioimmunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Italy Radioimmunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Russia Radioimmunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Nordic Countries Radioimmunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. China Radioimmunotherapy Market Size YoY (2018-2029) & (US$ Million)
Figure 33. China Radioimmunotherapy Market Share by Type (2018-2029)
Figure 34. China Radioimmunotherapy Market Share by Application (2018-2029)
Figure 35. Asia Radioimmunotherapy Market Size YoY (2018-2029) & (US$ Million)
Figure 36. Asia Radioimmunotherapy Market Share by Type (2018-2029)
Figure 37. Asia Radioimmunotherapy Market Share by Application (2018-2029)
Figure 38. Asia Radioimmunotherapy Market Share by Region (2018-2029)
Figure 39. Japan Radioimmunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. South Korea Radioimmunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. China Taiwan Radioimmunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Southeast Asia Radioimmunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. India Radioimmunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Australia Radioimmunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Middle East, Africa, and Latin America Radioimmunotherapy Market Size YoY (2018-2029) & (US$ Million)
Figure 46. Middle East, Africa, and Latin America Radioimmunotherapy Market Share by Type (2018-2029)
Figure 47. Middle East, Africa, and Latin America Radioimmunotherapy Market Share by Application (2018-2029)
Figure 48. Middle East, Africa, and Latin America Radioimmunotherapy Market Share by Country (2018-2029)
Figure 49. Brazil Radioimmunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 50. Mexico Radioimmunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 51. Turkey Radioimmunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 52. Saudi Arabia Radioimmunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 53. Israel Radioimmunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 54. GCC Countries Radioimmunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 55. Bayer Revenue Growth Rate in Radioimmunotherapy Business (2018-2024)
Figure 56. Novartis Revenue Growth Rate in Radioimmunotherapy Business (2018-2024)
Figure 57. Lantheus Revenue Growth Rate in Radioimmunotherapy Business (2018-2024)
Figure 58. Aurobindo Pharma Revenue Growth Rate in Radioimmunotherapy Business (2018-2024)
Figure 59. Mundipharma Revenue Growth Rate in Radioimmunotherapy Business (2018-2024)
Figure 60. China Isotope & Radiation Revenue Growth Rate in Radioimmunotherapy Business (2018-2024)
Figure 61. Curium Pharmaceuticals Revenue Growth Rate in Radioimmunotherapy Business (2018-2024)
Figure 62. Gilead Sciences Revenue Growth Rate in Radioimmunotherapy Business (2018-2024)
Figure 63. Clarity Pharmaceuticals Revenue Growth Rate in Radioimmunotherapy Business (2018-2024)
Figure 64. Curasight Revenue Growth Rate in Radioimmunotherapy Business (2018-2024)
Figure 65. Nordic Nanovector Revenue Growth Rate in Radioimmunotherapy Business (2018-2024)
Figure 66. Philogen Revenue Growth Rate in Radioimmunotherapy Business (2018-2024)
Figure 67. RadioMedix Revenue Growth Rate in Radioimmunotherapy Business (2018-2024)
Figure 68. Telix Pharmaceuticals Revenue Growth Rate in Radioimmunotherapy Business (2018-2024)
Figure 69. Orano Med Revenue Growth Rate in Radioimmunotherapy Business (2018-2024)
Figure 70. Actinium Pharmaceuticals Revenue Growth Rate in Radioimmunotherapy Business (2018-2024)
Figure 71. Y-mAbs Therapeutics Revenue Growth Rate in Radioimmunotherapy Business (2018-2024)
Figure 72. Fusion Pharmaceuticals Revenue Growth Rate in Radioimmunotherapy Business (2018-2024)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed